Will GiveWell fund Sayana® Press by 1st January 2027?
DRAFT
Main Draft
Log in to edit
23rd Oct
Josh Hart 13:49
GiveWell has recommended grants to over 10 charities over the years. They are currently investigating 12 charity areas with other areas of research in the pipeline including Sayana® Press.
“Worldwide in 2015, 12 per cent of married or in-union women are estimated to have had an unmet need for family planning; that is, they wanted to stop or delay childbearing but were not using any method of contraception. The level was much higher, 22 per cent, in the least developed countries. Many of the latter countries are in sub-Saharan Africa, which is also the region where unmet need was highest (24 per cent)...
**
**
Sayana® Press is a three-month, progestin-only, all-in-one injectable contraceptive that combines the drug and needle in the Uniject™ injection system.5 Sayana Press is small, light, easy to use, and requires minimal training, making it especially suitable for community-based distribution—and for women to administer themselves through self-injection…
**
**
Sayana Press delivers the drug depot medroxyprogesterone acetate (DMPA, also known under the brand name Depo-Provera®) through subcutaneous (SC) injection via PATH's Uniject™ single-use prefilled syringes.8 The United Kingdom's National Institute for Health and Care Excellence (NICE) reviewed the available evidence and concluded that DMPA, administered through subcutaneous (SC) or intramuscular (IM) injection, is an effective contraceptive…
**
**
[However,] Sayana Press is associated with several side effects, including headaches, bleeding irregularities, weight gain, injection-site reactions, and loss of bone mineral density (BMD) (which may increase the risk of bone fractures)...
**
**
We are highly uncertain about the costs of charities' Sayana Press programs, how many recipients of Sayana Press through these programs would not have used modern contraception in absence of the programs, and philosophical judgments on the value of averting unintended pregnancies and providing contraception relative to the outcomes of our priority programs.“
GiveWell has recommended grants to over 10 charities over the years. They are currently investigating 12 charity areas with other areas of research in the pipeline including Sayana® Press.
The following sections are quoted from GiveWell’s explanation of the topic:
“Worldwide in 2015, 12 per cent of married or in-union women are estimated to have had an unmet need for family planning; that is, they wanted to stop or delay childbearing but were not using any method of contraception. The level was much higher, 22 per cent, in the least developed countries. Many of the latter countries are in sub-Saharan Africa, which is also the region where unmet need was highest (24 per cent)...
** **
Sayana® Press is a three-month, progestin-only, all-in-one injectable contraceptive that combines the drug and needle in the Uniject™ injection system.5 Sayana Press is small, light, easy to use, and requires minimal training, making it especially suitable for community-based distribution—and for women to administer themselves through self-injection…
** **
Sayana Press delivers the drug depot medroxyprogesterone acetate (DMPA, also known under the brand name Depo-Provera®) through subcutaneous (SC) injection via PATH's Uniject™ single-use prefilled syringes.8 The United Kingdom's National Institute for Health and Care Excellence (NICE) reviewed the available evidence and concluded that DMPA, administered through subcutaneous (SC) or intramuscular (IM) injection, is an effective contraceptive…
** **
[However,] Sayana Press is associated with several side effects, including headaches, bleeding irregularities, weight gain, injection-site reactions, and loss of bone mineral density (BMD) (which may increase the risk of bone fractures)...
** **
We are highly uncertain about the costs of charities' Sayana Press programs, how many recipients of Sayana Press through these programs would not have used modern contraception in absence of the programs, and philosophical judgments on the value of averting unintended pregnancies and providing contraception relative to the outcomes of our priority programs.“